세계의 심방세동 시장 - 산업규모, 점유율, 동향, 기회, 예측, 치료유형별(약리학적 치료), 비약리학적 치료, 최종용도별, 지역별, 경쟁별(2020-2030년)

Atrial Fibrillation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type (Pharmacological Treatment ), Non-Pharmacological Treatment, By End-use, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,240,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,627,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,094,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

심방세동 세계 시장은 2024년 225억 4,000만 달러로 평가되었으며, 예측기간 동안 CAGR 7.19%로 성장할 것으로 예상되며, 2030년에는 341억 8,000만 달러에 이를 것으로 예측됩니다.

심방세동은 불규칙하고 종종 급속한 심박을 특징으로 하는 일반적인 심장부정맥이며, 뇌졸중, 심부전, 기타 심혈관 합병증의 리스크를 현저하게 증대시킵니다. 전 세계적으로 증가하는 발병률은 인구 고령화, 비만율 증가, 생활 방식으로 인한 건강 문제 등의 요인에 기인합니다. 이 상태는 의료 시스템에 상당한 임상적, 재정적 부담을 줍니다. COVID-19의 대유행은 심장 수술을 줄이는 한편, 원격 의료나 원격 모니터링과 같은 디지털 헬스 케어 접근 방식의 중요성을 강조했습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	225억 4,000만 달러
시장 규모 : 2030년	341억 8,000만 달러
CAGR : 2025-2030년	7.19%
급성장 부문	병원
최대 시장	북미

시장 성장 촉진요인

고령화 인구 증가가 세계 심방세동시장을 견인

주요 시장 과제

인지도 부족

주요 시장 동향

기술 진보

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 세계의 심방세동시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율 및 예측
  • 치료유형별(약물 치료(항부정맥제), 비약물 치료(카테터 절제, 메이즈 수술, 전기적 제세동))
  • 용도별(병원, 전문 클리닉, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 심방세동시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽 심방세동시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 심방 세동 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 심방세동시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 심방세동 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 합병과 인수
• 제품 개발
• 최근 동향

제13장 세계의 심방세동 시장 : SWOT 분석

제14장 경쟁 구도

• Parexel International Corporation
• AtriCure Inc.
• Boehringer Ingelheim GmbH
• Boston Scientific Corporation
• Bristol-Myers Squibb Corporation
• Cardio Focus Inc.
• Sanofi Aventis
• Biosense Webster Inc.
• Endoscopic Technologies Inc.
• Abbott Laboratories
• Johnsons & Johnson Services, Inc.

제15장 전략적 제안

제16장 기업 소개와 면책사항

SHW

영문 목차

영문목차

The Global Atrial Fibrillation Market was valued at USD 22.54 Billion in 2024 and is projected to reach USD 34.18 Billion by 2030, growing at a CAGR of 7.19% during the forecast period. Atrial fibrillation, a prevalent cardiac arrhythmia marked by irregular and often rapid heartbeats, significantly increases the risk of stroke, heart failure, and other cardiovascular complications. Its growing incidence globally is attributed to factors such as the aging population, increasing obesity rates, and lifestyle-induced health issues. This condition poses a considerable clinical and financial burden on healthcare systems. The COVID-19 pandemic, while reducing cardiac surgeries, emphasized the importance of digital healthcare approaches like telemedicine and remote monitoring-trends that are expected to persist and support market growth. As a result, the demand for effective atrial fibrillation management continues to rise, driving advancements in treatment and diagnosis.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 22.54 Billion
Market Size 2030	USD 34.18 Billion
CAGR 2025-2030	7.19%
Fastest Growing Segment	Hospital
Largest Market	North America

Key Market Drivers

Increasing Aging Population is Driving the Global Atrial Fibrillation Market

The growing global aging population is a major factor fueling the expansion of the atrial fibrillation market. Older individuals are more susceptible to this condition due to age-related health risks such as hypertension, obesity, and diabetes. As the proportion of elderly people rises, so does the prevalence of atrial fibrillation. According to the American Heart Association, the likelihood of developing atrial fibrillation doubles with every decade after age 50. Additionally, the World Health Organization reports that by 2030, one in six people globally will be over 60, with the number expected to reach 2.1 billion by 2050. This demographic trend is significantly influencing the demand for atrial fibrillation therapies and solutions.

Key Market Challenges

Lack of awareness

A major hurdle in combating atrial fibrillation globally is the widespread lack of awareness. Despite being common, the condition often goes undiagnosed or is insufficiently treated. This is largely due to limited public understanding of its symptoms and potential severity, resulting in delayed diagnoses and inadequate interventions. The insufficient awareness among both patients and healthcare providers continues to impede efforts to effectively manage and reduce the burden of atrial fibrillation worldwide.

Key Market Trends

Technological Advancements

Technological innovations are transforming the diagnosis and management of atrial fibrillation, leading to improved patient outcomes and more efficient healthcare delivery. As the most common form of cardiac arrhythmia, atrial fibrillation can result in serious complications, making early and accurate detection critical. Advanced tools and procedures, including minimally invasive surgical techniques and remote monitoring solutions, are gaining prominence. These developments cater to growing demand for safer, more precise treatment methods and are playing a pivotal role in expanding the global atrial fibrillation market.

Key Market Players

• Parexel International Corporation
• AtriCure Inc.
• Boehringer Ingelheim GmbH
• Boston Scientific Corporation
• Bristol- Myers Squibb Corporation
• Cardio Focus Inc.
• Sanofi Aventis
• Biosense Webster Inc.
• Endoscopic Technologies Inc.
• Abbott Laboratories
• Johnsons & Johnson Services, Inc.

Report Scope:

In this report, the Global Atrial Fibrillation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Atrial Fibrillation Market, By Treatment Type:

• Pharmacological Treatment
• Non-Pharmacological Treatment

Atrial Fibrillation Market, By End Use:

• Hospital
• Specialty Clinics
• Others

Atrial Fibrillation Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Atrial Fibrillation Market.

Available Customizations:

Global Atrial Fibrillation market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

4. Voice of Customer

5. Global Atrial Fibrillation Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type (Pharmacological Treatment (Anti-arrhythmic Drugs), Non-Pharmacological Treatment(Catheter Ablation, Maze Surgery, Electric Cardioversion)
  • 5.2.2. By End-use (Hospital, Specialty Clinics, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Atrial Fibrillation Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By End-Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Atrial Fibrillation Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By End-Use
  • 6.3.2. Canada Atrial Fibrillation Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By End-Use
  • 6.3.3. Mexico Atrial Fibrillation Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By End-Use

7. Europe Atrial Fibrillation Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By End-Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Atrial Fibrillation Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By End-Use
  • 7.3.2. United Kingdom Atrial Fibrillation Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By End-Use
  • 7.3.3. Italy Atrial Fibrillation Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By End-Use
  • 7.3.4. France Atrial Fibrillation Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By End-Use
  • 7.3.5. Spain Atrial Fibrillation Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By End-Use

8. Asia-Pacific Atrial Fibrillation Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By End-Use
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Atrial Fibrillation Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By End-Use
  • 8.3.2. India Atrial Fibrillation Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By End-Use
  • 8.3.3. Japan Atrial Fibrillation Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By End-Use
  • 8.3.4. South Korea Atrial Fibrillation Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment Type
      • 8.3.4.2.2. By End-Use
  • 8.3.5. Australia Atrial Fibrillation Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment Type
      • 8.3.5.2.2. By End-Use

9. South America Atrial Fibrillation Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By End-Use
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Atrial Fibrillation Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By End-Use
  • 9.3.2. Argentina Atrial Fibrillation Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By End-Use
  • 9.3.3. Colombia Atrial Fibrillation Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By End-Use

10. Middle East and Africa Atrial Fibrillation Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By End-Use
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Atrial Fibrillation Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By End-Use
  • 10.3.2. Saudi Arabia Atrial Fibrillation Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By End-Use
  • 10.3.3. UAE Atrial Fibrillation Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By End-Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition
• 12.2. Product Development
• 12.3. Recent Developments

13. Global Atrial Fibrillation Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Parexel International Corporation
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. AtriCure Inc.
• 14.3. Boehringer Ingelheim GmbH
• 14.4. Boston Scientific Corporation
• 14.5. Bristol- Myers Squibb Corporation
• 14.6. Cardio Focus Inc.
• 14.7. Sanofi Aventis
• 14.8. Biosense Webster Inc.
• 14.9. Endoscopic Technologies Inc.
• 14.10. Abbott Laboratories
• 14.11. Johnsons & Johnson Services, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료